LUXVIVO

About Vitanova Biomedical

Vitanova Biomedical is a private, preclinical-stage biotech founded in 2018 and based in San Antonio, Texas. The company is pioneering a 'veterinary-first' development strategy for its Light-Activated Intracellular Acidosis (LAIA) platform, initially targeting canine melanoma, hemangiosarcoma, and osteosarcoma. By securing FDA Center for Veterinary Medicine approval first, Vitanova aims to validate its technology, establish a regulatory blueprint, and generate early data to support future translation into human cancer therapies. The platform combines tumor-targeted nanoparticles with non-thermal laser activation to induce cancer cell death via intracellular acidosis.

About Vitanova Biomedical

Vitanova Biomedical is a private, preclinical-stage biotech founded in 2018 and based in San Antonio, Texas. The company is pioneering a 'veterinary-first' development strategy for its Light-Activated Intracellular Acidosis (LAIA) platform, initially targeting canine melanoma, hemangiosarcoma, and osteosarcoma. By securing FDA Center for Veterinary Medicine approval first, Vitanova aims to validate its technology, establish a regulatory blueprint, and generate early data to support future translation into human cancer therapies. The platform combines tumor-targeted nanoparticles with non-thermal laser activation to induce cancer cell death via intracellular acidosis.

About Vitanova Biomedical

Vitanova Biomedical is a private, preclinical-stage biotech founded in 2018 and based in San Antonio, Texas. The company is pioneering a 'veterinary-first' development strategy for its Light-Activated Intracellular Acidosis (LAIA) platform, initially targeting canine melanoma, hemangiosarcoma, and osteosarcoma. By securing FDA Center for Veterinary Medicine approval first, Vitanova aims to validate its technology, establish a regulatory blueprint, and generate early data to support future translation into human cancer therapies. The platform combines tumor-targeted nanoparticles with non-thermal laser activation to induce cancer cell death via intracellular acidosis.

Therapeutic Areas

Other Canine Melanoma Drugs